Reinfection in Patients with Lyme Disease

Nadelman, Robert B.; Wormser, Gary P.

doi:10.1086/521256

Cited by 74 publications

(54 citation statements)

References 44 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinically, no significant differences were detected regarding associated symptoms based on previous LB or not in this study. These findings are in line with data from a recent American study (Nadelman and Wormser, 2007).…”

Section: Discussionsupporting

confidence: 92%

Antibody responses to borrelia IR6 peptide variants and the C6 peptide in Swedish patients with erythema migrans

Tjernberg

Sillanpää

Seppälä

et al. 2009

International Journal of Medical Microbiology

View full text Add to dashboard Cite

The aim of this study was to evaluate the antibody responses to different VlsE protein IR6 peptide variants and the synthetic C6 peptide in acute and convalescent (2-3 and 6 months) serum samples from Swedish patients with clinical erythema migrans (EM). Serum samples were prospectively collected from 148 patients with EM and compared to serum samples obtained from 200 healthy blood donors. The IgG responses to 3 IR6 peptide variants originating from Borrelia burgdorferi (B. burgdorferi) sensu stricto, B. garinii, and B. afzelii were measured by enzyme-linked immunosorbent assays (ELISAs) and compared to a commercial C6 peptide ELISA. Seropositivity rate in the IR6 or C6 peptide ELISAs ranged from 32% to 58% at presentation, 30-52% after 2-3 months, and 20-36% after 6 months. At presentation, positive antibodies in any of the 4 ELISAs were found in 66%. In 7/52 (13%), C6-negative EM cases, serological reaction was found to the B. burgdorferi sensu stricto-derived IR6 peptide. In patients reporting previous LB compared to those without previous LB, significantly higher seropositivity rates were noted for all IR6 peptides, but not for the C6 peptide. In the serology of EM in Europe, C6 ELISA does not seem to cover all cases. An ELISA using a mixture of B. burgdorferi sensu stricto IR6 peptide and the C6 peptide could be of value in the serodiagnosis of LB in Europe. Further studies on combinations of variant IR6 peptides and the C6 peptide in other manifestations of LB are needed to address this issue.Original Publication:Ivar Tjernberg, H. Sillanpaa, I. Seppala, I. Eliasson, Pia Forsberg and P. Lahdenne, Antibody responses to borrelia IR6 peptide variants and the C6 peptide in Swedish patients with erythema migrans, 2009, International Journal of Medical Microbiology, (299), 6, 439-446.http://dx.doi.org/10.1016/j.ijmm.2008.10.006Copyright: Elsevier Science B. V. Amsterdamhttp://www.elsevier.com

show abstract

Section: Discussionsupporting

confidence: 92%

Antibody responses to borrelia IR6 peptide variants and the C6 peptide in Swedish patients with erythema migrans

Tjernberg

Sillanpää

Seppälä

et al. 2009

International Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…Adults and nymphs readily bite humans (Falco and Fish 1988) and in some endemic areas in the United States of America, repeated tick bites can be quite common (Nadelman and Wormser 2007). Dermal reactions in people to uninfected blacklegged tick bites are usually unremarkable but development of a tick-associated itch from repeated tick bites has been reported (Burke et al 2005).…”

Section: Ixodes (Ixodes) Scapularis Saymentioning

confidence: 99%

The Biological Survey of Canada: A Personal History

Danks¹

2017

View full text Add to dashboard Cite

“…Severe consequences of LB can affect the skin, nervous system, joints and heart [1,4]. Importantly, successful antibiotic therapy does not guarantee against reinfection [5].…”

Section: Editorialmentioning

confidence: 99%